Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

TOKYO, December 22, 2023--(BUSINESS WIRE)--Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., " Cellusion " ), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration ( " FDA " ) has granted Orphan Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials